[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492706":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":27,"responsibleParty":44,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Aalborg University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Intention-to-treat cohort",null,"All patients included",[13],{"name":14,"affiliation":15,"role":16},"Morten Ladekarl, MD, DMSCi","Department of Oncology, Aalborg University Hospital, Denmark","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Morten Ladekarl, MD, DMSci","CONTACT","+45 97660545","morten.ladekarl@rn.dk",{"name":24,"role":20,"phone":25,"phoneExt":10,"email":26},"Anja Pagh, MD, PhD","+45 97661417","a.pagh@rn.dk",[28],{"facility":29,"status":30,"city":31,"state":10,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Department of Oncology, Aalborg University Hospital","RECRUITING","Aalborg","9000","Denmark","DK",{"type":36,"coordinates":37},"Point",[38,39],9.9187,57.048,{"lat":39,"lon":38},[42,43],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},{"name":24,"role":20,"phone":25,"phoneExt":10,"email":26},{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Morten Ladekarl","Professor","100492706","proseq-cancer-genomic-profiling-in-patients-with-incurable-cancer-in-search-for-targeted-treatment-100492706",false,"NCT05695638","Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment","Proseq Cancer: A Prospective Study of Comprehensive Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment","Inclusion Criteria:\n\n* Incurable, progressing and\u002For life-threatening cancer\n* Expected residual survival of at least 3 months\n* No efficient remaining standard treatment options\n* Patient recruited from the Region of Northern Jutland, Denmark\n\nExclusion Criteria:\n\n* WHO Performance Status \\>2\n* Significant comorbidity, concurrent medication or laboratory values imposing an unacceptable risk at medical oncological treatment","ALL","18 Years",{"count":58,"type":59},3000,"ESTIMATED","5 Years","OBSERVATIONAL","Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region.\n\nTreatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.",[64,65],"Solid Tumor, Unspecified, Adult","Haematological Malignancy",[67,68,69,70],"Precision medicine","Personalized medicine","Genomic profiling","Tissue agnostic","2024-01-30",{"date":73,"type":74},"2024-01-31","ACTUAL",{"date":76,"type":74},"2020-07-01",{"date":78,"type":59},"2035-05-31",{"name":46,"class":6},1]